Production (Stage)
Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.55M | -20.54M | -20.98M | -17.01M | -15.66M |
| Total Depreciation and Amortization | 14.00K | 15.00K | 7.90K | 7.90K | 6.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.66M | 2.86M | 5.55M | 1.75M | 2.58M |
| Change in Net Operating Assets | -2.41M | -779.10K | 705.10K | 758.60K | -168.50K |
| Cash from Operations | -20.29M | -18.44M | -14.72M | -14.49M | -13.24M |
| Capital Expenditure | -2.90K | -3.90K | -4.60K | -12.10K | -14.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.40M | 5.03M | 457.80K | -12.52M | -14.25M |
| Cash from Investing | 6.40M | 5.03M | 453.20K | -12.54M | -14.26M |
| Total Debt Issued | -- | -- | 140.00K | 139.00K | 140.00K |
| Total Debt Repaid | -- | -- | -237.00K | -2.62M | -2.62M |
| Issuance of Common Stock | 43.64M | 43.64M | 2.92M | 2.70M | 35.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 9.85M | 9.85M | -3.19M | -2.83M | 15.50M |
| Cash from Financing | 38.21M | 38.21M | -270.30K | -1.94M | 35.87M |
| Foreign Exchange rate Adjustments | 336.80K | 217.80K | -1.22M | -85.60K | -963.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.66M | 25.02M | -15.76M | -29.05M | 7.40M |